Trial Profile

A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CVN-058 (Primary)
Indications Cognition disorders
Focus Therapeutic Use
Sponsors Cerevance

Most Recent Events

29 Jul 2021 Status changed from active, no longer recruiting to completed.
16 Nov 2020 Primary endpoint has been met. (Quantitative Electroencephalogram, Mismatch Negativity (MMN)), according to a Cerevance media release.
16 Nov 2020 Results presented in a Cerevance media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com